Similar articles for PMID: 32859702

Year	Number of Results
2002	1
2003	1
2006	1
2007	1
2008	3
2009	4
2010	2
2011	1
2012	1
2013	14
2014	8
2015	4
2016	14
2017	13
2018	11
2019	15
2020	22
2021	13
2022	17
2023	9
2024	0

1

High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT.

Werner RA, Derlin T, Rowe SP, Bundschuh L, Sheikh GT, Pomper MG, Schulz S, Higuchi T, Buck AK, Bengel FM, Bundschuh RA, Lapa C. Werner RA, et al. J Nucl Med. 2021 Apr;62(4):514-520. doi: 10.2967/jnumed.120.245464. Epub 2020 Aug 28. J Nucl Med. 2021. PMID: 32859702 Free PMC article.

2

Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients.

Grawe F, Ebner R, Geyer T, Beyer L, Winkelmann M, Sheikh GT, Eschbach R, Schmid-Tannwald C, Cyran CC, Ricke J, Bartenstein P, Heimer MM, Faggioni L, Spitzweg C, Fabritius MP, Auernhammer CJ, Ruebenthaler J. Grawe F, et al. Eur Radiol. 2023 May;33(5):3416-3424. doi: 10.1007/s00330-023-09518-y. Epub 2023 Mar 25. Eur Radiol. 2023. PMID: 36964768 Free PMC article.

3

Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on ¹⁸F-DCFPyL PET/CT Imaging.

Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Leal JP, Higuchi T, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Lapa C, Rowe SP. Werner RA, et al. J Nucl Med. 2018 Dec;59(12):1857-1864. doi: 10.2967/jnumed.118.217588. Epub 2018 Sep 6. J Nucl Med. 2018. PMID: 30190304 Free PMC article.

4

Training on Reporting and Data System (RADS) for Somatostatin-Receptor Targeted Molecular Imaging Can Reduce the Test Anxiety of Inexperienced Readers.

Weich A, Higuchi T, Bundschuh RA, Lapa C, Serfling SE, Rowe SP, Pomper MG, Herrmann K, Buck AK, Derlin T, Werner RA. Weich A, et al. Mol Imaging Biol. 2022 Aug;24(4):631-640. doi: 10.1007/s11307-022-01712-6. Epub 2022 Mar 1. Mol Imaging Biol. 2022. PMID: 35233654 Free PMC article.

5

High Interobserver Agreement on PSMA PET/CT Even in the Absence of Clinical Data.

Bundschuh RA, Lütje S, Bundschuh L, Lapa C, Higuchi T, Hartrampf PE, Gorin MA, Kosmala A, Buck AK, Pomper MG, Rowe SP, Essler M, Sheikh GT, Werner RA. Bundschuh RA, et al. Clin Nucl Med. 2023 Mar 1;48(3):207-212. doi: 10.1097/RLU.0000000000004524. Epub 2023 Jan 10. Clin Nucl Med. 2023. PMID: 36723879 Free PMC article.

6

SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework.

Werner RA, Solnes LB, Javadi MS, Weich A, Gorin MA, Pienta KJ, Higuchi T, Buck AK, Pomper MG, Rowe SP, Lapa C. Werner RA, et al. J Nucl Med. 2018 Jul;59(7):1085-1091. doi: 10.2967/jnumed.117.206631. Epub 2018 Mar 23. J Nucl Med. 2018. PMID: 29572257 Free article.

7

Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.

Thapa P, Ranade R, Ostwal V, Shrikhande SV, Goel M, Basu S. Thapa P, et al. Nucl Med Commun. 2016 Oct;37(10):1030-7. doi: 10.1097/MNM.0000000000000547. Nucl Med Commun. 2016. PMID: 27243215

8

Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients.

Versari A, Sollini M, Frasoldati A, Fraternali A, Filice A, Froio A, Asti M, Fioroni F, Cremonini N, Putzer D, Erba PA. Versari A, et al. Thyroid. 2014 Apr;24(4):715-26. doi: 10.1089/thy.2013.0225. Epub 2013 Nov 14. Thyroid. 2014. PMID: 24102584 Clinical Trial.

9

68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients.

Fendler WP, Barrio M, Spick C, Allen-Auerbach M, Ambrosini V, Benz M, Bluemel C, Grewal RK, Lapa C, Miederer M, Nicolas G, Schuster T, Czernin J, Herrmann K. Fendler WP, et al. J Nucl Med. 2017 Feb;58(2):307-311. doi: 10.2967/jnumed.116.179192. Epub 2016 Aug 18. J Nucl Med. 2017. PMID: 27539839 Free PMC article.

10

Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.

Jois B, Asopa R, Basu S. Jois B, et al. Clin Nucl Med. 2014 Jun;39(6):505-10. doi: 10.1097/RLU.0000000000000429. Clin Nucl Med. 2014. PMID: 24662668

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

127 results

Results by year